Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a formulation study partnership with Eli Lilly and Company.
CAMBRIDGE, United Kingdom, May 20, 2021 (GLOBE NEWSWIRE) -- Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study partnership with Eli Lilly and Company (“Lilly”).
Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, thermostable formulation of one of Lilly’s proprietary products intended for self-administration. The thermostable formulation would allow greater convenience of use of the product by patients, whilst maintaining its integrity. Lilly will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialise the product.
Arestat™ is an innovative and proprietary formulation technology platform which enhances the properties of therapeutic proteins, peptides and vaccines. Arecor applies the Arestat™ technology to deliver superior reformulations of existing products as well as improving properties of new products in development.
Sarah Howell, Chief Executive Officer of Arecor, said: “We are delighted to be collaborating with Lilly again. We have always had a strong working relationship and we believe that our Arestat™ technology has the potential to deliver a new formulation that can improve the convenience of use of this critical self-administered product for Lilly’s patients. This collaboration with Lilly augments our partnership portfolio of major pharmaceutical companies and demonstrates how our formulation expertise can provide novel medical solutions for our partners.”
| For more information, please contact: | |
| Arecor Limited | www.arecor.com |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 |
| Email: sarah.howell@arecor.com | |
| Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 |
| Email: susan.lowther@arecor.com | |
| Mo Noonan, Communications | Tel: +44 (0) 7876 444977 |
| Email: mo.noonan@arecor.com | |
| Consilium Strategic Communications | |
| Chris Gardner, David Daley, Angela Gray | Tel: +44 (0) 20 3709 5700 |
| Email: arecor@consilium-comms.com |
Notes to Editors
About Arecor
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
For further details please see our website, www.arecor.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
